Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Open accessThe DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Abstract
: 1. After 50 years of antipsychotic drug development focused on the dopamine D2 receptor, schizophrenia remains a chronic, disabling disorder for most affected individuals. 2. Studies over the last decade demonstrate that administration of low doses of NMDA receptor antagonists can cause in normal subjects the negative symptoms, cognitive impairments and physiologic disturbances observed in schizophrenia. 3. Furthermore, a number of recently identified risk genes for schizophrenia affect NMDA receptor function or glutamatergic neurotransmission. 4. Placebo-controlled trials with agents that directly or indirectly activate the glycine modulatory site on the NMDA receptor have shown reduction in negative symptoms, improvement in cognition and in some cases reduction in positive symptoms in schizophrenic patients receiving concurrent antipsychotic medications. 5. Thus, hypofunction of the NMDA receptor, possibly on critical GABAergic inter-neurons, may contribute to the pathophysiology of schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overactivity of NMDA receptors causing excitotoxicity is a proposed underlying mechanism for epilepsy, dementia, and stroke, whereas low activity produces symptoms of schizophrenia.2–4”
From Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies (2008) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The prefrontal cortex (PFC) and hippocampus stand out as major regions affected in schizophrenia”
From Adolescent Onset of Cortical Disinhibition in Schizophrenia: Insights From Animal Models (2011) · cites this paper as [3]
In the citing paper
“A loss of scaffolding proteins in spines could alter glutamatergic receptor signaling, disruption of which is theorized to contribute to the etiology of schizophrenia60.”
From Dendritic spine pathology in neuropsychiatric disorders (2011) · cites this paper as [60]
In the citing paper
“Overactivity of NMDA receptors causing excitotoxicity is a proposed underlying mechanism for epilepsy, dementia, and stroke, whereas low activity produces symptoms of schizophrenia.2–4”
From Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies (2008) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892 · cited 1×
“Existing drugs are poorly tolerated and exhibit little differences in efficacy (Lieberman et al., 2005).”
BackgroundKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 2×
“Newcomer et al. (1999) extended the findings of Krystal et al. (1994) by showing that declarative memory, the form impaired in schizophrenia, was quite sensitive to low dose ketamine infusion.”
BackgroundRecent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904 · cited 1×
“Based upon the emerging pharmacology of the NMDAR, Javitt and Zukin (1991) proposed that the psychotomimetic effects of PCP were due to blockade of the NMDA receptors.”
BackgroundTripartite synapses: glia, the unacknowledged partner
Araque, A., Parpura, V., Sanzgiri, R. P., & Haydon, P. G. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01349-6 · Cited by 2,529 · cited 1×
“The glutamatergic synapse consists of a tight functional relationship among the presynaptic terminal, the postsynaptic spine and the ensheathing astrocyte end-foot (Araque et al., 1999; Coyle et al., 2002).”
BackgroundSchizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
The hippocampal-VTA loop: controlling the entry of information into long-term memory
Lisman, J. E., & Grace, A. A. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.002 · Cited by 1,983
Braff, D. L., Geyer, M. A., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100810 · Cited by 1,705
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393 · cited 2×
“In addition, clozapine treatment has been associated with reduction in the rate of suicide, reduction in smoking and reduction in abuse of other substances in schizophrenic patients (Drake et al., 2000; Meltzer et al., 2003; Zimmet et al., 2000).”
BackgroundLesion of striatal neurons with kainic acid provides a model for Huntington's chorea
COYLE, J. T., & SCHWARCZ, R. (1976) · Nature · doi:10.1038/263244a0 · Cited by 1,248 · cited 1×
“We focused on glutamatergic signal transduction before there was any evidence that it could be relevant to neuropsychiatric disorders (Coyle and Schwarcz, 1976).”
BackgroundSelf-citation
Research works printed but not linked: 1
- Wang, X., He, G., Gu, N., Yang, J., Tang, J., Chen, Q., et al. (2004). Association of G72/G30 with schizophrenia in the Chinese population. Biochem. Biophys. Res. Commun. 319:1281–1286. · DOI
Cited by
Items 701–800 of 954
Ramazi, S., آرانی, ف., Safaei, A., Abbasi, Z., Heidari, Z., Nafchi, H. G., Mohammadsadeghi, H., & Karimzadeh, F. (2021) · The Neuroscience Journal of Shefaye Khatam · doi:10.52547/shefa.9.2.119 · Cited by 5
Alterations of Neurotransmitter Receptors in Schizophrenia: Evidence from Postmortem Studies
Kristiansen, L. V., Cowell, R. M., Biscaia, M., McCullumsmith, R. E., & Meador‐Woodruff, J. H. (2009) · Springer eBooks · doi:10.1007/978-0-387-30410-6_14 · Cited by 6
Gottschalk, M. G., Sarnyai, Z., Guest, P. C., Harris, L. W., & Bahn, S. (2012) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/s0101-60832012005000007 · Cited by 9
Schizophrenia and Affective Disorders
Picker, J. D. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-383834-6.00117-8 · Cited by 5
Mouffok, I., Lahogue, C., Cailly, T., Fréret, T., Bouët, V., & Boulouard, M. (2024) · Brain Sciences · doi:10.3390/brainsci14121281 · Cited by 4
Exosomes as Emerging Therapeutic Platforms in Neurological and Psychiatric Disorders
Kumar, R. M. R., Logesh, R., & Chidambaram, S. B. (2025) · Pharmaceutical Medicine · doi:10.1007/s40290-025-00584-9 · Cited by 4
“Elevated levels of miR-223 have been linked to sustained hypofunction of the N -methyl- d -aspartate receptor (NMDAR), resulting in reduced synaptic activity [65].”
Rice, C. A., & Stackman, R. W. (2026) · Biology · doi:10.3390/biology15030222 · Cited by 4
“…first-and second-generation antipsychotic treatments offer limited efficacy for the negative and cognitive symptoms associated with schizophrenia [42–45], highlighting a major limitation of the dopamine-centered model, and the need for more focused preclinical research into the neurobiological…”
Thomsen, M. S., Hansen, H. H., & Mikkelsen, J. D. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.08.013 · Cited by 6
Synaptic Plasticity in the Hippocampus
Bliss, T., Collingridge, G. L., Cooke, S. F., Georgiou, J., & Morris, R. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780190065324.003.0010 · Cited by 5
Glutamatergic Modulation of Brain Function in Psychosis: A Systematic Review of Neuroimaging Studies
Varvari, I., Bolte, L., Colli, C., Mancini, V., Nour, M. M., McGuire, P. K., & McCutcheon, R. A. (2025) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2025.07.004 · Cited by 7
“Multiple lines of evidence from animal studies, genetic models, postmortem analyses, and neuroimaging suggest that glutamatergic dysfunction may contribute to cognitive and negative symptoms and treatment-resistant positive symptoms (3,12).”
Aslan, A., Hatırnaz-Ng, Ö., Taşar, O., Özbek, U., & Yamantürk-Çelik, P. (2023) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2023.173688 · Cited by 4
Pharmacology and Neuroscience of Antipsychotic Drugs
Waddington, J. L., O’Tuathaigh, C. M. P., & Remington, G. J. (2010) · Wiley eBooks · doi:10.1002/9781444327298.ch23 · Cited by 5
Mahdavi, A., Bahrami, F., & Janahmadi, M. (2015) · National and International Iranian Conference on Biomedical Engineering (ICBME) · doi:10.1109/icbme.2015.7404120 · Cited by 4
“Glutamate hypothesis expresses that there is a hypofunction in NMDA receptors [7].”
BackgroundSLC1A1 Gene Variants and Normal Tension Glaucoma: An Association Study
真美, 西., Meguro, A., Nomura, E., Yamane, T., Takeuchi, M., Ôta, M., Kashiwagi, K., Mabuchi, F., Iijima, H., Kawase, K., et al. (2016) · Ophthalmic Genetics · doi:10.3109/13816810.2015.1028649 · Cited by 4
“On the basis of pharmacological evidence, dysfunction of glutamate neurotransmission has been implicated in the pathophysiology of schizophrenia.(28) EAAC1-deficient mice have been reported to exhibit reduced neuronal glutathione levels, and, with aging, develop brain atrophy and behavioral changes.”
BackgroundGlutamate Concentration in the Superior Temporal Sulcus Relates to Neuroticism in Schizophrenia
Balz, J., Romero, Y. R., Keil, J., Schubert, F., Ittermann, B., Mekle, R., Montag, C., Gallinat, J., & Senkowski, D. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.00578 · Cited by 4
“Frontiers in Psychology | www.frontiersin.org 1 May 2018 | Volume 9 | Article 578 The glutamate hypothesis posits changes in glutamatergic synapses and alterations in glutamatergic pathways in SCZ (Coyle, 2006; Javitt, 2010; Kantrowitz and Javitt, 2010; Poels et al., 2014a,b).”
BackgroundRavindren, R. K., Shibukumar, T. M., Lekshmi, B., & Jose, K. (2018) · Journal of Psychosocial Rehabilitation and Mental Health · doi:10.1007/s40737-018-0116-2 · Cited by 4
“The current antipsychotic drugs have limited efficacy in ameliorating cognitive and negative symptoms [6].”
BackgroundSutter, J., Chindo, B. A., & Becker, A. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.04.008 · Cited by 4
Hu, C.-C., Pan, X., Zhang, M., & Chen, H. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i24.8648 · Cited by 4
Chen, E. Y. H., Wong, S. M. Y., Tang, E. Y. H., Lei, K. S., Suen, Y. N., & Hui, C. L. M. (2023) · Brain Sciences · doi:10.3390/brainsci13071069 · Cited by 6
L-Glutamate Biosensor for In Vitro Investigations: Application in Brain Extracts
Razumienė, J., Leo, D., Gurevičienė, V., Ratautas, D., Gaidukevič, J., & Šakinytė, I. (2023) · Chemosensors · doi:10.3390/chemosensors11080418 · Cited by 5
Développement d’un antipsychotique : nouvelles directions
Krebs, M. (2008) · Therapies · doi:10.2515/therapie:2008031 · Cited by 4
Acute psychosis in anti-NMDA-receptor encephalitis
Sacré, K., Lidove, O., Chanson, N., Laganier, J., Vidailhet, M., Lejoyeux, M., & Papo, T. (2011) · La Presse Médicale · doi:10.1016/j.lpm.2011.05.010 · Cited by 5
Metabotropic Receptors for Glutamate and GABA
Stewart, G. D., Kniazeff, J., Przeau, L., Rondard, P., Pin, J., & Goudet, C. (2012) · InTech eBooks · doi:10.5772/32481 · Cited by 5
“One potential mode of treating schizophrenia lies within targeting GABAergic and glutamateric interneuons in pivotal cortical and limbic regions, specifically, the disregulation of the disinhibition of glutamatergic neurotransmission (Chavez-Noriega et al., 2002; Coyle, 2006).”
BackgroundDion, S., Barbe, P. G., Leman, S., Camus, V., & Dimier‐Poisson, I. (2009) · médecine/sciences · doi:10.1051/medsci/2009258-9687 · Cited by 4
“Infection par Toxoplasma gondii et tropisme cérébral Il existerait un tropisme plus spécifique du parasite pour certaines structures cérébrales, plus particulièrement les structures amygdaliennes [29, 41], zones subissant des modifications morphologiques et neurobiologiques chez les schizophrènes [42].”
BackgroundDiscontinued drugs in 2005: schizophrenia drugs
Kerwin, R. W. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.12.1487 · Cited by 4
“This is based on the psychotomimetic potential of drugs acting at the NMDA receptor, postmortem findings and the action of antipsychotics on postmortem systems [20].”
BackgroundNeuroprotective effects of methanol extract of Terminalia macroptera leaf in mice
Ior, L. D., Sunday, O. O., & John, S. G. (2020) · African Journal of Pharmacy and Pharmacology · doi:10.5897/ajpp2020.5160 · Cited by 4
“Author(s) agree that this article remain permanently open access under the terms of the Creative Commons Attribution License 4.0 International License however, the cellular and molecular pathology of psychosis is yet to be sufficiently understood (Coyle, 2006: Stahl, 2007; Chatterjee et al., 2012).”
BackgroundInfluentialAbortion and infertility in Russia.
Kulakov, V. I. (1995) · PubMed · Cited by 4
Molecular Genetics of Schizophrenia: Focus on Symptom Dimensions
Ritsner, M. S., & Susser, E. (2009) · Springer eBooks · doi:10.1007/978-90-481-2298-1_4 · Cited by 5
Maintaining and Modifying Connections: Roles for Axon Guidance Cues in the Mature Nervous System
Thompson‐Steckel, G., & Kennedy, T. E. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.212 · Cited by 4
Acute Behavioral and Neurochemical Effects of Sulpiride in Adult Zebrafish
Galstyan, D. S., Lebedev, A. S., Ilyin, N. P., Papulova, M. S., Golushko, N. I., Tishkina, V. V., Saklakova, D. K., Martynov, D. D., Kolesnikova, T. O., Rosemberg, D. B., et al. (2024) · Neurochemical Research · doi:10.1007/s11064-024-04268-9 · Cited by 3
Recent Advances in Schizophrenia Genomics and Emerging Clinical Implications
Bigdeli, T. B., & Harvey, P. D. (2025) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2025.01.008 · Cited by 3
Leana-Sandoval, G., Madrid, A., Kolli, A. V., Chinn, C. A., Sandoval, M. A., Lo, I., Vera, V. A., Simms, J. A., Wood, M. A., & Díaz-Alonso, J. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03328-y · Cited by 3
Developing tomorrow's antipsychotics: the need for a more personalised approach
Hunter, R. (2014) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.110.008235 · Cited by 3
Taylor, M. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-401688-0.00016-1 · Cited by 4
Naringin processing using GAS antisolvent technique and in vivo applications
de Oliveira, P. V., Dias, J. L., Sakata, G. S. B., Aguiar, G. P. S., Kuhn, K. Z., Sanaiotto, O., Provinelli, A. C., Daniel, C., Bortoluzzi, A. J., Precisvalle, N., et al. (2023) · The Journal of Supercritical Fluids · doi:10.1016/j.supflu.2023.106148 · Cited by 3
Craven, A. R., Dwyer, G. E., Ersland, L., Kazimierczak, K., Lilleskare, L., Noeske, R., Sandøy, L. B., Johnsen, E., & Hugdahl, K. (2025) · Scientific Reports · doi:10.1038/s41598-025-03644-x · Cited by 3
“This may reflect reduced glutamine demand, perhaps as a result of N-methyl-D-aspartic acid (NMDA) receptor hypofunction 74 , leading to a net accumulation of glutamine 73 .”
Parametric and pharmacological modulations of latent inhibition in mouse inbred strains
Lipina, T. V., Rasquinha, R. J., & Roder, J. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.08.023 · Cited by 4
Rethinking the Contribution of Neuroimaging to Translation in Schizophrenia
Tost, H., Zangl, M., & Meyer‐Lindenberg, A. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-386945-6.00006-8 · Cited by 3
Deviance Detection Property in Dissociated Cultures of Neurons
Kubota, T., Sakurayama, K., Shiramatsu, T. I., & Takahashi, H. (2021) · IEEJ Transactions on Electronics Information and Systems · doi:10.1541/ieejeiss.141.661 · Cited by 3
Lopes, J. J., Rae, C. D., Meyer, D., Yolland, C. O. B., Neill, E., Castle, D. J., Dean, B., & Rossell, S. L. (2024) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2024.111926 · Cited by 4
“Growing evidence suggests that dysregulation in the glutamate system may contribute to the pathophysiology of schizophrenia (Coyle, 2006; Egerton and Stone, 2012).”
Biochemical and genetic aspects of pathogenesis of schizophrenia
Камбарова, Д. К., & Golubev, A. G. (2011) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s0022093011050021 · Cited by 4
“These effects are suggested to be realized at the level of the NMDA-receptors in GABAergic interneurons; for this, of importance are only some subpopulations of such neurons [12].”
BackgroundModafinil: A Candidate for Pharmacotherapy of Negative Symptoms in Schizophrenia
Peloian, J. H., & Pierre, J. M. (2007) · Progress in Neurotherapeutics and Neuropsychopharmacology · doi:10.1017/s1748232107000134 · Cited by 3
Avila-Rojas, S. H., Sandoval, H., & Pérez‐Neri, I. (2016) · PubMed · Cited by 7
Neurocognitive Deficits, Negative Symptoms, and Insight in Schizophrenia
Preda, A., Bota, R. G., & Harvey, P. D. (2011) · Springer eBooks · doi:10.1007/978-94-007-0831-0_2 · Cited by 5
“individuals that are a close analogue to schizophrenia, including positive and negative symptoms, impairments in communication, and cognitive deficits [101].”
BackgroundSchizophrenia, Oxidative Stress and Selenium
Pitts, M. W., Raman, A. V., & Berry, M. J. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1025-6_28 · Cited by 4
Arroyo, J. L. B., Malmierca, E. F., Cubides, A. C., Ramón, G. L., & Jimeno, A. (2010) · Actas Españolas de Psiquiatría · Cited by 4
The Effect of Ketamine on Configural Facial Processing
Neill, E., Joshua, N. R., Morgan, C. J. A., & Rossell, S. L. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000278 · Cited by 3
Jalali, S. (2013) · International Neuropsychiatric Disease Journal · doi:10.9734/indj/2013/6192 · Cited by 3
“Tests exploring the antipsychotic efficacy of Cannabidiol utilise either human models hitherto afflicted with psychoses or humans/animals artificially with artificially induced psychosis following exposure to psychotomimetic substances, which are believed to emulate a certain component of the hypothesised aetiological…”
BackgroundResultBanerjee, A., Borgmann‐Winter, K. E., Ray, R., & Hahn, C.-G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801829-3.00016-1 · Cited by 3
Mori, H. (2017) · Springer eBooks · doi:10.1007/978-3-319-49795-2_1 · Cited by 3
Baturina, M., Beyer, E., Батурин, В. А., & Popov, A. (2020) · Medical news of the North Caucasus · doi:10.14300/mnnc.2020.15073 · Cited by 3
Geerts, H., Roberts, P., & Spiros, Ä. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.04.001 · Cited by 3
Mallien, A. S., Pfeiffer, N., Vogt, M. A., Chourbaji, S., Sprengel, R., Gass, P., & Inta, D. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.750106 · Cited by 3
Neurodevelopmental Theories of Schizophrenia: Twenty‐First Century Perspectives
Haut, K. M., Schvarcz, A., Cannon, T. D., & Bearden, C. E. (2016) · Wiley eBooks · doi:10.1002/9781119125556.devpsy223 · Cited by 3
Hook, P. W., & McCallion, A. S. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/427484 · Cited by 3
Formation and synaptic control of active transient working memory representationsPreprint
Becker, S., Nold, A., & Tchumatchenko, T. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.30.273995 · Cited by 3
Sheffler, D. J., & Conn, P. J. (2010) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0346-0241-9_6 · Cited by 2
“1) [3, 32, 34, 35, 45–48].”
BackgroundG Protein-coupled Receptors (GPCRs) as Potential Therapeutics for Psychiatric Disorders
Sharaf, S. E. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527322666230403130324 · Cited by 2
Lorenzi, R. M., Grazia, M. D., Wheeler‐Kingshott, C. A. M. G., Palesi, F., D'Angelo, E. U., & Casellato, C. (2026) · Neural Networks · doi:10.1016/j.neunet.2026.109872 · Cited by 2
Yılmaz, M. A., Kaya, H., Aşut, G., Çiftçi, H. Ö., Bayram, Ş., Oğuz, E. F., Turhan, T., & Göka, E. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.07.053 · Cited by 2
Zahid, U., Osugo, M., Selvaggi, P., Lythgoe, D. J., Fortunato, C., Diederen, K. M. J., Kiemes, A., Wall, M. B., Whitehurst, T., Onwordi, E. C., et al. (2025) · The British Journal of Psychiatry · doi:10.1192/bjp.2025.10319 · Cited by 2
Vunck, S. A., Wiebelhaus, J. M., Arnt, J., & Porter, J. H. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.10.022 · Cited by 2
S-ketamine for the treatment of depression
Järventausta, K., Kampman, O., Yli‐Hankala, A., & Leinonen, E. V. J. (2015) · Cited by 2
Landmark, C. J., & Johannessen, S. I. (2010) · Springer eBooks · doi:10.1007/978-90-481-8553-5_16 · Cited by 2
“Both GABA and glutamate contribute to the control of dopaminergic activity in the brain that is thought to be hyperactive in schizophrenia [39, 43 , 47].”
BackgroundTreatment of Schizophrenia in the 21st Century: Towards a more Personalised Approach
Hunter, R. (2012) · InTech eBooks · doi:10.5772/36078 · Cited by 4
“Dopamine dysregulation is likely to be a ‘downstream’ or a secondary consequence of the primary biological causes of the condition (Coyle, 2006).”
BackgroundDissecting the Molecular Causes of Schizophrenia
Wildenauer, D. B., Wildenauer, D. M. B., & Schwab, S. G. (2008) · Nucleic acids and molecular biology · doi:10.1007/978-3-540-85383-1_2 · Cited by 2
“The excitatory glutaminergic system is also interconnected with the GABA system (Coyle 2006).”
BackgroundAltamura, A. C. (2011) · Neuropsychiatry · doi:10.2217/npy.11.58 · Cited by 2
“127 Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry 158(9), 1367–1377 (2001).”
BackgroundMemantine as a neuroprotective agent in early phases of psychosis
Fusar‐Poli, P., Pellegrini, F., & Cortesi, M. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.07.026 · Cited by 2
Klug, M., Hill, R., & van den Buuse, M. (2015) · Springer eBooks · doi:10.1007/978-3-319-17103-6_24 · Cited by 3
Can Oxytocin Enhance Social Affiliation in Schizophrenia?
Bhat, I., Buckner, A., & Ara, A. (2016) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-016-0080-7 · Cited by 2
Behavioral Phenotypes of Genetic Mouse Models
Moran, P. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801829-3.00029-x · Cited by 3
Meeting Emerging Challenges and Opportunities in Psychiatry Through Computational Neuroscience
Anticevic, A., Krystal, J. H., & Murray, J. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809825-7.02004-6 · Cited by 2
Spider toxins targeting ligand-gated ion channels
Filchakova, O. (2019) · Toxin Reviews · doi:10.1080/15569543.2019.1579230 · Cited by 2
Zieba, J., Morris, M. J., & Karl, T. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112074 · Cited by 3
Özkul, T., & GÖLGELİ, A. (2019) · Mersin üniversitesi sağlık bilimleri dergisi/Mersin üniversitesi sağlık bilimleri dergisi · doi:10.26559/mersinsbd.517921 · Cited by 3
EEG Connectivity Pattern: A Window into the Schizophrenia Mind?
Steinmann, S., Nolte, G., & Mulert, C. (2020) · Springer eBooks · doi:10.1007/978-3-030-35206-6_13 · Cited by 3
Cellular and Circuit Models of Increased Resting State Network Gamma Activity in Schizophrenia
White, R. S., & Siegel, S. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801829-3.00022-7 · Cited by 4
Autoimmune encephalitis in psychiatric institution (clinical case)
Khannanova, A. N., Nabiev, S. R., Fominykh, V., Golyakhovskaya, A. Y., & Brylev, L. (2022) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202212201249 · Cited by 2
Genetic Influences on Cognitive Dysfunction in Schizophrenia
Greenwood, T. A. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_388 · Cited by 2
The Role of Neuregulin 1 in Schizophrenia: A Bioinformatics ApproachPreprint
Dias, Á. M., Maracaja‐Coutinho, V., & Lopo, A. (2009) · Nature Precedings · doi:10.1038/npre.2009.3905.1 · Cited by 2
“…levels of free glutamate, which affect synaptic and dendrite structure, reduce signaling propagation through action potentials (as it impairs retransmission along WM Ranvier nodes) and in certain circumstances induce severe apoptosis (for a review: Bubeníková-Valesová, et al, 2008; Coyle, 2006).”
BackgroundThe implosion of reality: schizophrenia, the anterior cingular cortex and anticipation
Grave, D. D. (2006) · Ghent University Academic Bibliography (Ghent University) · Cited by 3
High prevalence of the antibody against Syncytin-1 in schizophreniaPreprint
Hibi, Y., Asamitsu, K., Matsumura, H., Sanda, T., Nakahira, Y., Arimoto, K., Nakanishi, S., Maekawa, K., Akechi, T., Matsukawa, N., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/266049 · Cited by 3
“acid receptor (NMDAR) antibodies in SZ patients (van Mierlo et al, 2015; Kristiansen et al, 2007; Coyle, 2006).”
BackgroundChiu, C., Wong, K., Lai, M., & Lai, Y.-M. (2022) · Hong Kong Journal of Radiology · doi:10.12809/hkjr2117278 · Cited by 1
Sapp, C., Rich, M. E., Hess, K., Losco, A., Zupancic, A., & Caldwell, H. K. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110442 · Cited by 1
“While both clinical and preclinical work has implicated the dopaminergic (Howes and Kapur, 2009; Seeman, 1987) and glutamatergic (Coyle, 2006; Moghaddam and Javitt, 2011) systems as major contributors to the pathology of schizophrenia, there is evidence that other neurotransmitter systems may also…”
Rogóż, Z., Kamińska, K., & Wąsik, A. (2025) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2025.174028 · Cited by 1
Yu, M., Tan, Q., Dong, W., & Xiang, B. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06867-y · Cited by 1
Wenjing, D., & Bao, T. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041749 · Cited by 1
“Following the dopamine hypothesis, the excitation–inhibition imbalance hypothesis emerged, suggesting that the glutamatergic and gamma-aminobutyric acid (GABAergic) systems are dysregulated [144,145].”
Costa, B. M., Davis, J. L., Hines, D., Anandakrishnan, R., & Tuohy, J. L. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.104787 · Cited by 1
Imaging of CNS Systems: Importance for Drug Development
Wan, H. I., Kling, M. A., Day, M., Chavez, J. C., Feuerstein, G., Hurko, O., & Pangalos, M. N. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0134-7_2 · Cited by 1
“Several lines of evidence also point to dysfunction in glutamatergic systems as a factor underlying the neurocognitive deficits associated with schizophrenia (Coyle 2006).”
BackgroundClozapine Combinations in Treatment-Resistant Schizophrenia Patients
Lerner, V., & Miodownik, C. (2012) · Springer eBooks · doi:10.1007/978-94-007-5799-8_7 · Cited by 1
Inhibition of Glycine Transporter-1 Improves the Functional Outcome of Schizophrenia
Hui, C., & Tsai, G. E. (2010) · Springer eBooks · doi:10.1007/978-90-481-8553-5_19 · Cited by 1
1H MRSI and social communication deficits in pediatric complex partial seizures
O’Neill, J., Seese, R. R., Hudkins, M. R., Siddarth, P., Levitt, J. G., Tseng, P. B., Wu, K. N., Gurbani, S. G., Shields, W. D., & Caplan, R. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03114.x · Cited by 1
“This receptor has been implicated in both pediatric epilepsy (Najm et al., 2004; Rho, 2004) and schizophrenia (Coyle et al., 2003; Coyle, 2006).”
BackgroundAbazyan, S., & Pletnikov, M. V. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.017 · Cited by 1
Autoimmune Epilepsy: New Development and Future Directions
Orozco-Suárez, S. A., Vega-García, A., Feria-Romero, I. A., Arriaga‐Pizano, L., Rodriguez-Chavez, E., & Grijalva, I. (2018) · InTech eBooks · doi:10.5772/intechopen.70686 · Cited by 1
Nalakonda, G., Islam, M., Chukwu, V. E., Soliman, A., Munim, R., & Abukraa, I. (2018) · Cureus · doi:10.7759/cureus.3091 · Cited by 2
Jeon, P. (2019) · Scholarship@Western (Western University) · Cited by 1
Ichinose, M. C., & Park, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815012-2.00002-x · Cited by 1
Li, Q., Chan, W. M., Rudd, J. A., Wang, C. M., Lam, P. Y. H., Wai, M. S. M., Wood, D. M., Dargan, P. I., & Yew, D. T. W. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415816-0.00012-2 · Cited by 2
Nörobilim Ve Psikiyatri Hemşireliğinde Kullanımı: Hayal Ya Da Gerçek?
Aslan, R., & Arslantaş, H. (2022) · Sakarya Medical Journal · doi:10.31832/smj.790693 · Cited by 3
Browman, K. E., Zhang, M., Fox, G. B., & Rueter, L. E. (2008) · CRC Press eBooks · doi:10.1201/9781420053937-11 · Cited by 1
Metadata
- Authors
- Coyle, J. T.
- Affiliations
- Harvard University (US)
- Corresponding author
- Coyle, Joseph T.
- ORCID
- Coyle, Joseph T.
- Venue
- Cellular and Molecular Neurobiology
- Published
- 2006-06-14
- Volume
- 26
- Issue
- 4-6
- Pages
- 363-382
- ISSN
- 0272-4340 (ISSN-L)
- 1573-6830
- PMC
- PMC11881825
- OpenAlex
- W2008639041
- Cited by
- 917
- References
- 159
- Citations by year
- 2026: 13 · 2025: 27 · 2024: 16 · 2023: 29 · 2022: 29 · 2021: 28 · 2020: 35 · 2019: 47 · 2018: 43 · 2017: 44 · 2016: 45 · 2015: 56 · 2014: 47 · 2013: 74 · 2012: 62
- FWCI
- 7.68
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Cellular and Molecular Neurobiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (P50MH060450, MH P50-60450, MH R01-572901)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- schizophrenia, glutamate, NMDA receptor, dopamine hypothesis, negative symptoms, cognitive impairment, NMDA receptor antagonists, schizophrenia risk genes, GABAergic interneurons, antipsychotic drugs, glutamatergic neurotransmission
- MeSH terms
- Animals, Dopamine, Glutamates, Humans, Models, Biological, Synaptic Transmission, Schizophrenia, Antipsychotic Agents, Receptors, N-Methyl-D-Aspartate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.